The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19 x CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of, in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, "BiTE") is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.USO DEL ANTICUERPO BLINATUMOMAB (MT-103) EN COMBINANCIÓN CON DEXAMETOSONA EN EL TRATAMIENTO DE LA MASA TUMORAL DE TEJIDO DE GANGLIOS LINFÁTICOS Y/O LINFOMA EXTRADONAL CAUSADO POR EL LINFOMA B DIFUSO DE CÉLULAS GRANDES (LBDCG) PARA DISMINUIR EFECTOS NEUROLOGICOS ADVERSOS； TRATAMIENTOS TERAPÉUTICOS
